These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 37976112)
1. The impact of C-reactive protein levels on the effectiveness of upadacitinib in patients with rheumatoid arthritis: a 12-month prospective, non-interventional German study. Witte T; Kiltz U; Haas F; Riechers E; Prothmann U; Adolf D; Holland C; Rössler A; Soppa U; Fritz B; Götz K; Krüger K; Clin Exp Rheumatol; 2024 Mar; 42(3):726-735. PubMed ID: 37976112 [TBL] [Abstract][Full Text] [Related]
2. Discontinuation of methotrexate in rheumatoid arthritis patients achieving clinical remission by treatment with upadacitinib plus methotrexate (DOPPLER study): A study protocol for an interventional, multicenter, open-label and single-arm clinical trial with clinical, ultrasound and biomarker assessments. Shimizu T; Kawashiri SY; Sato S; Kawazoe Y; Kuroda S; Kawasaki R; Ito Y; Morimoto S; Yamamoto H; Kawakami A Medicine (Baltimore); 2022 Jan; 101(2):e28463. PubMed ID: 35029189 [TBL] [Abstract][Full Text] [Related]
3. Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial. van Vollenhoven R; Strand V; Takeuchi T; Chávez N; Walter PM; Singhal A; Swierkot J; Khan N; Bu X; Li Y; Penn SK; Camp HS; Aelion J Arthritis Res Ther; 2024 Jul; 26(1):143. PubMed ID: 39075620 [TBL] [Abstract][Full Text] [Related]
4. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Burmester GR; Kremer JM; Van den Bosch F; Kivitz A; Bessette L; Li Y; Zhou Y; Othman AA; Pangan AL; Camp HS Lancet; 2018 Jun; 391(10139):2503-2512. PubMed ID: 29908669 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials. Song GG; Choi SJ; Lee YH Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506 [TBL] [Abstract][Full Text] [Related]
8. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230 [TBL] [Abstract][Full Text] [Related]
9. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. Rubbert-Roth A; Enejosa J; Pangan AL; Haraoui B; Rischmueller M; Khan N; Zhang Y; Martin N; Xavier RM N Engl J Med; 2020 Oct; 383(16):1511-1521. PubMed ID: 33053283 [TBL] [Abstract][Full Text] [Related]
10. Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND. van Vollenhoven RF; Hall S; Wells AF; Meerwein S; Song Y; Tanjinatus O; Fleischmann R RMD Open; 2024 Jul; 10(3):. PubMed ID: 39053948 [TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Fleischmann RM; Genovese MC; Enejosa JV; Mysler E; Bessette L; Peterfy C; Durez P; Ostor A; Li Y; Song IH Ann Rheum Dis; 2019 Nov; 78(11):1454-1462. PubMed ID: 31362993 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. Kameda H; Takeuchi T; Yamaoka K; Oribe M; Kawano M; Zhou Y; Othman AA; Pangan AL; Kitamura S; Meerwein S; Tanaka Y Rheumatology (Oxford); 2020 Nov; 59(11):3303-3313. PubMed ID: 32277824 [TBL] [Abstract][Full Text] [Related]
13. Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting. Baker JF; Bakewell C; Dikranian A; Lam G; O'Brien J; Moore PC; Yu M; Hur P; Masri KR Rheumatol Ther; 2024 Jun; 11(3):841-853. PubMed ID: 38507187 [TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study. Rubbert-Roth A; Kato K; Haraoui B; Rischmueller M; Liu Y; Khan N; Camp HS; Xavier RM Rheumatol Ther; 2024 Oct; 11(5):1197-1215. PubMed ID: 39031276 [TBL] [Abstract][Full Text] [Related]
15. Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study. Takeuchi T; Rischmueller M; Blanco R; Xavier RM; Ueki Y; Atsumi T; Chen S; Friedman A; Pangan AL; Strand V; van Vollenhoven RF Mod Rheumatol; 2021 May; 31(3):534-542. PubMed ID: 33164611 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study. Fleischmann R; Meerwein S; Charles-Schoeman C; Combe B; Hall S; Khan N; Carter KM; Camp HS; Rubbert-Roth A RMD Open; 2024 Jul; 10(3):. PubMed ID: 39059811 [TBL] [Abstract][Full Text] [Related]
17. Relative remission rates of Janus kinase inhibitors in comparison with adalimumab in patients with active rheumatoid arthritis: a network meta-analysis. Lee YH; Song GG Z Rheumatol; 2024 Feb; 83(Suppl 1):88-96. PubMed ID: 35142908 [TBL] [Abstract][Full Text] [Related]
18. Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials. Bergman M; Buch MH; Tanaka Y; Citera G; Bahlas S; Wong E; Song Y; Zueger P; Ali M; Strand V Rheumatol Ther; 2022 Dec; 9(6):1517-1529. PubMed ID: 36125701 [TBL] [Abstract][Full Text] [Related]
19. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Emery P; Burmester GR; Bykerk VP; Combe BG; Furst DE; Barré E; Karyekar CS; Wong DA; Huizinga TW Ann Rheum Dis; 2015 Jan; 74(1):19-26. PubMed ID: 25367713 [TBL] [Abstract][Full Text] [Related]
20. Tofacitinib versus methotrexate as the first-line disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: An open-label randomized controlled trial. Khan MM; Ahmed S; Hasan Sajib MK; Morshed AA; Mahbub-Uz-Zaman K; Haq SA Int J Rheum Dis; 2023 Sep; 26(9):1729-1736. PubMed ID: 37377385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]